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Abstract
Objective Modern PET/CT scanners have significantly
improved detectors and fast time-of-flight (TOF) perfor-
mance and this may improve clinical performance. The aim
of this study was to analyze the impact of a current gen-
eration TOF PET/CT scanner on standardized uptake val-
ues (SUV), lesion-background contrast and
characterization of the adrenal glands in patients with
suspected lung cancer, in comparison with literature data
and commonly used SUV cut-off levels.
Methods We included 149 adrenal glands from 88
patients with suspected lung cancer, who underwent 18F-
FDG PET/CT. We measured the SUVmax in the adrenal
gland and compared this with liver SUVmean to calculate
the adrenal-to-liver ratio (AL ratio). Results were com-
pared with literature derived with older scanners, with
SUVmax values of 1.0 and 1.8 for normal glands [1, 2].
Final diagnosis was based on histological proof or follow-
up imaging. We proposed cut-off values for optimal sep-
aration of benign from malignant glands.
Results In 127 benign and 22 malignant adrenal glands,
SUVmax values were 2.3 ± 0.7 (mean ± SD) and
7.8 ± 3.2 respectively (p\ 0.01). Corresponding AL
ratios were 1.0 ± 0.3 and 3.5 ± 1.4 respectively
(p\ 0.01). With a SUVmax cut-off value of 3.7, 96 %
sensitivity and 96 % specificity was reached. An AL ratio
cut-off value of 1.8 resulted in 91 % sensitivity and 97 %
specificity. The ability of both SUVmax and AL ratio to
separate benign from malignant glands was similar (AUC
0.989 vs. 0.993, p = 0.22).
Conclusions Compared with literature based on the pre-
vious generation of PET scanners, current generation TOF
18F-FDG PET/CT imaging provides higher SUVs for
benign adrenal glands, while it maintains a highly accurate
distinction between benign and malignant glands. Clinical
implementation of current generation TOF PET/CT
requires not only the use of higher cut-off levels but also
visual adaptation by PET readers.
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Introduction
Metastatic spread in non-small cell lung cancer (NSCLC)
typically involves the brain, bone, liver, contralateral lung
and adrenal glands [3]. An accurate evaluation of the
adrenal glands is important, especially when the glands are
enlarged on computed tomography (CT) [4, 5].
The adrenal glands can be characterized with several
imaging techniques, like CT, magnetic resonance imaging
(MRI), positron emission tomography (PET) using the
tracer fluorine-18 fluordeoxyglucose (18F-FDG) and com-
bined 18F-FDG PET/CT. All these techniques are capable
of distinguishing benign from malignant adrenal masses,
although with different degrees of accuracy [6]. Especially
18F-FDG PET/CT performs well and is often used for this
purpose as it is part of standard clinical practice in NSCLC.
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The combination of the small size of the normal adrenal
gland with the low 18F-FDG uptake make the glands usu-
ally invisible on older PET scanners because of relatively
low resolution. In 2004, a paper about the appearance of
the normal adrenal gland on 18F-FDG PET was published,
which reported an average maximum standardized uptake
value (SUVmax) around 1.0 [1]. More recently, Kim et al.
reported an average SUVmax value around 1.8 for normal
glands [2]. The introduction of combined PET/CT made
the evaluation of adrenal glands with 18F-FDG PET easier
because the location of tracer uptake could now be more
accurately assigned to the adrenal gland as seen on CT [1].
The visual aid provided by CT therefore led to a larger
proportion of gland visualization, although 18F-FDG
uptake was still similar to the PET/CT era. Furthermore, it
was demonstrated that the use of combined PET/CT
improved the distinction between benign and malignant
adrenal masses [7, 8].
In the past decade, however, PET technology itself has
been upgraded with new, faster scintillators like Lutetium-
Orthosilicate (LSO) and Lutetium-Yttrium-Orthosilicate
(LYSO). As a consequence, time-of-flight (TOF) PET
became the new standard technology for PET manufac-
turers. Generally, incorporation of the TOF technique leads
to a more accurate determination of the origin of the
annihilation event [9], resulting in improved measurements
of 18F-FDG uptake.
Even more recently, TOF performance is steadily
improving in newer scanners. A recently introduced TOF
PET/CT scanner (Ingenuity TF, Philips Healthcare) has a
time-of-flight performance with a timing resolution of
around 500 picoseconds [10], which translates to a location
uncertainty of 7.5 cm on lines-of-response. The improved
temporal resolution induces a higher signal-to-noise ratio,
higher spatial resolution and improved PET image quality
[11].
Therefore, the current generation of PET scanners may
lead to a better detection of the adrenal glands as well as
other small lesions. Therefore, the aim of this investigation
was to analyze the impact of a current generation TOF
PET/CT scanner on SUVs, lesion-to-background levels and
characterization of adrenal glands in patients with clini-
cally suspected lung cancer.
Materials and methods
Patients
We included 88 patients, referred for a whole-body 18F-
FDG PET/CT scan, to evaluate clinically suspected lung
cancer. Only patients harboring at least one adrenal gland
with a final diagnosis, based on histological proof or
follow-up imaging, were selected for this study. For 27
patients who underwent a single adrenal gland biopsy, no
follow-up imaging was available resulting in an unknown
status for the contralateral gland that was not invasively
evaluated. Consequently, in these patients, only the adrenal
gland with histological proof was included.
We received a waiver from the Medical Ethical Com-
mittee of our institution to perform this partly retrospective
and prospective study, as it only deals with additional
evaluation of a clinical indicated scan. However, all
patients agreed to the use of their data by signing an
informed consent form.
PET/CT data acquisition
Patients fasted for at least 6 h prior to scanning. Before
intravenous injection of 18F-FDG, blood glucose levels
were measured to ensure a value below 15 mmol/L. A
dedicated dose protocol depending quadratically on
patients’ body weight, as recently proposed in the literature
[12], was routinely used. It is described by the formula
A 9 t = 3.8 9 w2, where A is the 18F-FDG dose to
administer (in MBq), t the time per bed position (in sec-
onds) and w is the patients’ body weight (in kilogram).
All PET/CT scans were acquired with a current gener-
ation PET/CT scanner (Ingenuity TF, Philips Healthcare,
Cleveland, OH, USA). This fully three-dimensional TOF
scanner is combined with a 128-slice CT scanner. The PET
system contains 28,336 LYSO crystals (size
4 9 4 9 22 mm) divided across 44 detector rings.
Regarding TOF performances, the timing resolution of the
PET scanner is 495 picoseconds with a TOF localization-
accuracy of 7.4 cm. The PET scan was performed using a
whole-body PET/CT acquisition protocol with 50 % bed-
overlap. Acquisition times for the patient studies were 1
and 2 min per bed position for patients with body weight
B80 and [80 kg, respectively. The average administered
18F-FDG activity was 330 MBq (range 154–557 MBq).
Prior to PET imaging, a CT scan was acquired for
attenuation correction. The CT scan parameters were: tube
voltage 120 kV, average tube current 61 mA (range
36–140 mA), slice collimation 64 9 0.625 mm, pitch 0.83
and rotation time 0.5 s. The average CT dose-index was
4.1 mGy (range 2.5–9.3) with an average dose-length
product of 438 mGy cm (range 250–930).
PET/CT data reconstruction
PET data were reconstructed using the default reconstruc-
tion algorithm ‘‘Blob-OS-TF’’, a 3D ordered subset itera-
tive TOF reconstruction technique [13, 14]. For all
reconstructions, 3 iterations and 43 subsets were applied.
PET images were reconstructed in 144 9 144 matrices
146 Ann Nucl Med (2016) 30:145–152
123
with voxel size 4 9 4 9 4 mm3 and relaxation parameter
1.0. The blob had a 2.5 mm radius with a blob shape
parameter of 8.4 mm. Point-spread function modeling was
not applied.
Raw CT data were reconstructed using an iterative
reconstruction algorithm (iDose, Philips Healthcare,
Cleveland, OH, USA) with iDose level 4 and a slice
thickness of 3 mm. The acquisition- and reconstruction
protocol were both compatible with the guidelines of the
European Association of Nuclear Medicine (EANM) [15].
PET/CT data analysis
Integrated PET/CT data were reviewed on a dedicated
workstation (IntelliSpace Portal 6, Philips Healthcare,
Cleveland, OH, USA). The attenuation CT scan was used
to identify the adrenal glands and to characterize the gland
as normal sized or enlarged. The adrenal gland was
regarded as enlarged when an adrenal mass of at least 1 cm
was detected on an axial CT slice.
When histological evidence was not available, adrenal
glands were considered benign when they were stable in
size and had identical 18F-FDG uptake on follow-up
imaging. Adrenal glands were considered malignant when
there was progression in size or 18F-FDG uptake had
increased as evaluated by experienced readers. Further-
more, in patients who received systemic treatment during
the follow-up period, glands were considered malignant
when they showed a decrease in size or 18F-FDG uptake on
follow-up imaging.
Quantitative PET measurements were performed by an
experienced PET reader, blinded to histological and fol-
low-up findings, who measured the uptake on the axial
slice through the adrenal with the highest visual uptake.
Around the adrenal, an elliptical 2D region-of-interest
(ROI) was drawn that included at least two-thirds of the
gland. After accurate placement of the adrenal ROI was
confirmed on axial PET/CT images, the SUVmax within the
ROI was determined.
Furthermore, we performed background measurements
in a homogenous region in the liver. On the axial PET
image containing the largest liver area, we drew a circular
2D ROI of 2000 mm2 (5 cm diameter) in the right liver
lobe and measured the mean standardized uptake value
(SUVmean) within this ROI. We made sure that this liver
section was homogeneous on 18F-FDG PET and free of any
tumor or benign abnormality. For each adrenal gland, the
adrenal-liver ratio (AL ratio) was derived by dividing
adrenal gland SUVmax by liver SUVmean.
Data analysis
We calculated average SUVmax and AL ratio values for
benign and malignant adrenal glands, including a sub-
analysis for normal-sized and enlarged glands. We deter-
mined the sensitivity and specificity of SUVmax and AL
ratio for adrenal gland characterization at various cut-off
levels, using the final diagnosis as a reference standard. For
both parameters, the area under the curve (AUC) with the
95 % confidence-interval (CI) was provided.
Statistical analysis
Results were presented as mean ± standard deviation
(SD). Furthermore, ranges (minimum–maximum) in uptake
values were included. We applied the Independent samples
Mann–Whitney U test to compare the SUVmax and AL
ratio between benign and malignant glands and normal-
sized and enlarged glands, respectively. To evaluate dif-
ferences in characterization performance between SUVmax
and AL ratio, we compared the AUCs for both parameters
using a Chi-square test. A p value less than 0.05 was
considered to indicate statistical significance.
Results
Patient characteristics
Clinical data from 88 patients and 149 evaluated adrenal
glands are presented in Table 1. All adrenal glands were
identified on PET/CT images. There were 22 malignant and
127 benign glands. 91 % (20/22) of the malignant glands
were enlarged. Conversely, 40 % (20/50) of the enlarged
glands were malignant. For 76 % of the adrenal glands
(113/149) the final diagnosis was based on follow-up
imaging. The average follow-up period was 6.1 months,
which is fairly long in relation to the general rate of pro-
gression of lung cancer.
Average uptake values for benign and malignant
glands
Table 2 contains average SUVmax and AL ratios for benign
(n = 127) and malignant (n = 22) adrenal glands. For both
parameters, we found significantly higher uptake values for
malignant glands as compared to benign glands
(p\ 0.001), but with a wide range in uptake values for
both groups as visualised in Fig. 1.
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Normal-sized and enlarged adrenal glands
In Table 3, average SUVmax and AL ratios for normal-
sized (n = 99) and enlarged (n = 50) glands are presented.
In enlarged glands, we found significantly higher uptake
values when they were malignant (p\ 0.001). In normal-
sized malignant glands, we also observed higher uptake
values as compared to normal-sized benign glands,
although the number of normal-sized malignant glands was
limited (n = 2).
Furthermore, for enlarged benign glands there were
slightly higher uptake values as compared to normal-sized
benign glands (p = 0.01 for SUVmax and p\ 0.001 for AL
ratio, respectively). For both groups of benign glands, there
was a wide range in uptake values as visualised in Fig. 2.
Adrenal gland visualization with 18F-FDG PET/CT
Figure 3 contains 18F-FDG PET/CT images of three
patients with benign normal-sized, benign enlarged and
malignant adrenal glands. These examples present the
typical visualization of adrenal glands as visualised on 18F-
FDG TOF PET/CT imaging.
Table 1 Summary of patient characteristics




Age (years) 66 ± 11
Bodyweight (kg) 78 ± 15
Glucose (mmol/L) 6.1 ± 1.4
Follow-up period (months) 6.1 ± 2.4










Enlarged glands (n = 50)
Benign 30
Malignant 20
Table 2 SUVmax and AL ratios








Mean ± SD 2.3 ± 0.7 7.8 ± 3.2 p\ 0.001
Range 1.4–5.2 3.0–16.1
AL ratio
Mean ± SD 1.0 ± 0.3 3.5 ± 1.4 p\ 0.001
Range 0.5–2.3 1.6–6.7
Fig. 1 Box plots of the adrenal gland SUVmax (a) and AL ratios
(b) for benign and malignant adrenal glands. *Significant difference
(p\ 0.001) in SUVmax and AL ratio between benign and malignant
glands. Circle o values that are between 1.5 and 3.0 box length from
the percentile borders. Asterisk values that fall more than 3.0 box
length outside the box borders
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Adrenal gland characterization
Both the SUVmax and the AL ratio provided an accurate
separation of benign from malignant glands. For the
SUVmax, a cut-off value of 3.7 resulted in both 96 %
sensitivity and specificity. Using a lower SUVmax of 3.0,
100 % sensitivity was reached. However, this resulted in
only 84 % specificity. Furthermore, a higher SUVmax of 5.7
resulted in 100 % specificity with 77 % sensitivity.
For the AL ratio, a cut-off value of 1.8 resulted in 91 %
sensitivity and 97 % specificity. Using a lower AL ratio of
1.6, 100 % sensitivity was reached with 92 % specificity.
Furthermore at AL ratio 2.4, 100 % specificity was reached
with 86 % sensitivity.
The Chi-square test showed that the ability of both
SUVmax and AL ratio to separate benign from malignant
glands was similar (p = 0.22) with AUC values 0.989 (CI
0.974–1.000) and 0.993 (CI 0.983–1.000), respectively.
Discussion
The present study shows that the use of current generation
TOF PET/CT imaging yields higher SUVs in benign
adrenal glands, as compared to values described in the
literature based on the previous generation of PET scan-
ners. Consequently, the visualization of normal glands on
current generation TOF PET/CT has improved. Although
theoretically the improved visualization of benign glands
may lead to confusion, it appeared that the ability of 18F-
FDG PET to distinguish between benign and malignant
nature of the adrenal lesions remains very high, as SUVs in
malignant glands is also significantly higher than before.
Using appropriate cut-off values, 96 % sensitivity and
96 % specificity can be reached, which leads to an accurate
detection of metastatic adrenal gland lesions with modern
PET/CT.
This study can be regarded as an update of published
results in adrenal glands based on older PET/CT technol-
ogy. Results from the present study differ in many aspects
from previous investigations described in literature. For
example, we found statistically different SUVs between
normal-sized and enlarged benign glands (p = 0.01) which
has been described before; however, in our study the mean
difference in SUV between these groups was relatively
small (SUV 2.3 vs. SUV 2.6). For enlarged adrenal glands
(also mentioned adrenal lesions, nodules or masses), it is
known that they may show an increased 18F-FDG uptake
when benign [16, 17] and our results are comparable with
values reported in the literature. However, for normal-sized
Table 3 SUVmax and AL ratios for normal-sized and enlarged, benign and malignant glands
Normal-sized glands p value Enlarged glands p value
Benign (n = 97) Malignant (n = 2) Benign (n = 30) Malignant (n = 20)
SUVmax
Mean ± SD 2.3 ± 0.6 5.5 ± 0.8 p\ 0.001 2.6 ± 0.7 8.0 ± 3.3 p\ 0.001
Range 1.4–4.6 4.9–6.1 1.4–5.2 3.0–16.1
AL ratio
Mean ± SD 1.0 ± 0.3 2.8 ± 0.6 p\ 0.001 1.3 ± 0.3 3.6 ± 1.4 p\ 0.001
Range 0.5–1.9 2.4–3.3 0.8–2.3 1.6–6.7
Fig. 2 Box plots of the adrenal
gland SUVmax (a) and AL ratios
(b) for normal-sized and
enlarged benign adrenal glands.
*Significant difference in
SUVmax (p = 0.01) and AL
ratio (p\ 0.001) between
normal-sized and enlarged
benign glands. Circle o values
that are between 1.5 and 3.0 box
length from the percentile
borders. Asterisk values that fall
more than 3.0 box length
outside the box borders
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glands, an average SUVmax of 2.3 as found in our study is
considerably higher than values of 1.0 and 1.8 as reported
in the literature [1, 2]. In other words, with current gen-
eration TOF PET/CT there is an increase in measured
SUV, especially for normal-sized benign glands. Their
SUVs get closer to the commonly reported uptake values
for enlarged benign glands.
Furthermore, our study revealed a broad range (1.4–5.2)
in SUVmax for benign adrenal glands. The presence of a
wide range in uptake values has been mentioned before [1,
2], but with much smaller ranges (0.95–2.46 and 1.0–3.3,
respectively). Higher SUVs in normal-sized benign adrenal
glands, as found in the present study, are likely caused by
the improved resolution of current PET cameras with fast
TOF providing a better image quality for more accurate
SUV measurements [18]. Also the reduced partial volume
effect contributes to the more accurate evaluation of small
organs such as the adrenals.
Fig. 3 Single 18F-FDG PET (left) and fused 18F-FDG PET/CT
(right) images of three patients. a Two normal-sized adrenal glands
(arrows) are visualised. Uptake values for the left adrenal gland were
3.4 (SUVmax) and 1.2 (AL ratio). For the right adrenal gland, the
SUVmax and AL ratio were 3.2 and 1.1 respectively. A 6-months
follow-up 18F-FDG PET/CT scan did not reveal any changes in
adrenal gland size, shape and 18F-FDG uptake for both adrenal
glands. b Patient with an enlarged left adrenal gland (arrow), axial
diameter 32 mm. Average uptake values were 2.6 (SUVmax) and 1.0
(AL ratio). A biopsy performed during endoscopic ultrasound was
negative for tumor cells. Furthermore, 3-month follow-up 18F-FDG
PET/CT imaging did not reveal metastatic disease in this enlarged
adrenal gland. c Patient with a metastatic lesion in the left adrenal
gland. On 18F-FDG PET images, we measured a SUVmax of 4.9 and
an AL ratio of 3.3 for this adrenal gland. A biopsy performed during
endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
confirmed the presence of an adrenal metastasis, originating from a
lung tumor
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In simplified terms, using older generation of PET
scanners a clearly visualized adrenal could often times
safely and correctly be reported as malignant. With the
modern scanners, however, this is no longer the case. PET
readers should be aware of higher SUVs as well as wider
ranges in benign adrenal glands when evaluating scans
acquired with current generation TOF PET/CT. Readers
should also update their cut-off levels if they decide to use
SUV measurements to assist the visual diagnosis. It is
expected that this new particular knowledge improves the
diagnostic confidence of PET readers and prevents
unnecessary adrenal gland biopsies when implementing
current generation TOF PET/CT.
The main advantage of 18F-FDG PET/CT in adrenal
gland evaluation is the ability to detect and exclude
metastatic disease. Therefore, our finding that normal
adrenal glands show higher 18F-FDG uptake values on TOF
PET/CT may make interpretation more difficult, as it can
be hypothesized that the presence of higher SUVs in nor-
mal adrenal glands makes the distinction between benign
glands and (small) adrenal metastases more difficult.
However, in our study uptake in malignant glands was also
considerably higher and overall, we showed that 18F-FDG
PET/CT still has a great ability to detect metastatic disease
in adrenal glands, with 96 % sensitivity and 96 % speci-
ficity at a SUVmax cut-off level of 3.7. Many studies
described lower SUVmax cut-off values ranging between
2.5 and 3.4 [2, 7, 19–22]. Furthermore, one study reported
an optimal SUVmax of 3.9 with a relative poor performance
(sensitivity 96 %, specificity 82 %) [23] while another
study recently found sensitivity and specificity values of
90 % using SUVmax cut-off 5.2 [18].
Apart from the use of SUVmax in image interpretation,
adrenal gland uptake is always visually or quantitatively
compared with tracer intensity in the liver. In the present
study, SUVmax and AL ratio performances for adrenal
gland characterization were comparable. Nonetheless,
some studies suggested that the AL ratio is the most
accurate parameter for gland characterization [18, 23, 24].
In the past 15 years, many studies used a visual or quan-
titative AL ratio equal to or larger than 1.0 as cut-off value
to separate benign from malignant adrenal glands [5, 8, 24,
25]. In contrast, our study indicates that an AL ratio of at
least 1.6 should be used for accurate distinction while
recently, two other studies reported AL ratios of 1.4 and 1.5
with sensitivity and specificity values above 90 % [18, 23].
Hence, this demonstrates that clinical implementation of
current generation TOF PET/CT requires higher AL ratio
cut-offs than used to the past, which demands a change in
both quantitative and visual adrenal gland assessment by
PET readers.
In this study we demonstrated that the current generation
TOF PET/CT scanner is highly accurate in adrenal gland
characterization. However, we also found a wide range in
benign gland SUVs with some overlap in malignant gland
SUVs. Therefore, when a gland with a SUV ranging
between 3 and 6 is suspected to be the only metastatic
location in a patient, the status is still often verified by
biopsy (for left-sided glands) or short term follow-up
imaging (for right-sided glands), despite the very high
detection performance of PET.
The present study has some limitations. With an average
follow-up of 6 months, the follow-up period in this study
may be short, potentially biasing the results. However, on
average NSCLC rapidly progresses even after chemother-
apy. It seems unlikely that a normal sized metastatic gland
remains unchained in this period, although we cannot
completely exclude this possible small error. Furthermore,
the diagnostic performance might be further improved if
we would take additional information such as adrenal gland
Hounsfield measurements and contrast washout into
account [5, 7, 21]. Moreover, we focused on quantitative
assessment of the adrenal glands, while visual adrenal-to-
background evaluation on 18F-FDG PET remains important
and sensitive in clinical practice [19, 26]. Finally, adrenal
gland uptake may differ depending on the populations
studied [2].
Conclusion
Current generation TOF 18F-FDG PET/CT imaging results
in higher SUVs and adrenal-to-liver ratios in benign
adrenal glands, as compared to literature based on older
scanners. This leads to an improved visualization of both
benign and malignant glands and requires adaptation of
PET readers when evaluating current generation TOF PET/
CT images. However, this study indicates that the quanti-
tative differentiation between benign and malignant glands
in patients with suspected lung cancer remains highly
accurate, when appropriate cut-off levels are used.
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